These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17896963)

  • 1. The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection.
    Djordjevic A; Veljkovic M; Antoni S; Sakarellos-Daitsiotis M; Krikorian D; Zevgiti S; Dietrich U; Veljkovic N; Branch DR
    Curr HIV Res; 2007 Sep; 5(5):443-8. PubMed ID: 17896963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease.
    Veljkovic N; Branch DR; Metlas R; Prljic J; Manfredi R; Stringer WW; Veljkovic V
    J Clin Virol; 2004 Dec; 31 Suppl 1():S39-44. PubMed ID: 15567092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
    Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
    Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
    Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
    Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease.
    Veljkovic V; Metlas R
    Int Rev Immunol; 2004; 23(5-6):437-45. PubMed ID: 15370275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera.
    Metlas R; Trajkovic D; Srdic T; Veljkovic V; Colombatti A
    AIDS Res Hum Retroviruses; 1999 May; 15(7):671-7. PubMed ID: 10331446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 gp120.
    Vujicić AD; Gemović B; Veljković V; Glisić S; Veljković N
    Vojnosanit Pregl; 2014 Apr; 71(4):352-61. PubMed ID: 24783415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
    Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ
    AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells.
    Robey FA; Robert-Guroff M
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):533-41. PubMed ID: 11350667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people.
    Brown L; Souberbielle BE; Marriott JB; Westby M; Desselberger U; Kaye T; Gougeon ML; Dalgleish A
    AIDS; 1999 Dec; 13(18):2515-21. PubMed ID: 10630520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies].
    Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI
    Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1).
    Neurath AR; Strick N; Jiang S
    Virology; 1992 May; 188(1):1-13. PubMed ID: 1373549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120.
    Veliković V; Metlas R; Danilo V; Cavor L; Pejinović N; Dujuć A; Zakhariev S; Guarnaccia C; Pongor S
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1019-24. PubMed ID: 8250861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease.
    Veljkovic N; Branch DR; Metlas R; Prljic J; Vlahovicek K; Pongor S; Veljkovic V
    J Pept Res; 2003 Oct; 62(4):158-66. PubMed ID: 12969195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.